Diversity in Industrial Clinical Trials and Clinical Research

Submit Abstract Register Now

The clinical trial industry is constantly evolving with diversified clinical research technologies and new clinical studies are being launched at an ever-growing pace. Clinical trials have always been a vital part of the medicine development process, as they provide clinical data on the best ways for treating pathological disorders and diseases. The importance of diversity in industrial clinical trials and clinical research is to ensure that industrial clinical trials are doing due diligence and being as strategic as possible in their results. This diversity makes us to better understand the unmet medical needs of patients.

Market Analysis:

The global clinical trials market size was valued at USD 40.0 billion in 2016 and is expected to grow at a CAGR of 5.7% over the forecast period. According to BioOutsource, the demand for Biosimilars testing is expected to increase in the U.S. This is attributed to the fact that the FDA finally started addressing the lack of clear guidance with regards to biosimilars, specifically how the developers should prove that their drugs are similar to that of the originator product. In January 2015, Hospira submitted one of the biosimilar versions of Epogen (Epoetin Alfa) and the result of the review in the U.S. is anticipated from the FDA within a year.

Related Companys: Chiltern, Charles River Laboratories, PPD, Icon, inVentiv Health, Parexel, Covance, Quintiles

Societies and Associations: Academy of Physicians in Clinical Research (APCR), American Association for Cancer Research (AACR), American Federation for Medical Research (AFMR), American Statistical Association (ASA), American Society for Clinical Investigation (ASCI), Association of Clinical Research Organizations in the Netherlands (ACRON), Society for Clinical Data Management (ACDM), Association of CROs Czech Republic (ACRO-CZ).